Keratitis - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Keratitis - Pipeline Review, H2 2016

Keratitis - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Keratitis - Pipeline Review, H2 2016
Published Oct 29, 2016
70 pages — Published Oct 29, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Keratitis Pipeline Review, H2 2016, provides an overview of the Keratitis (Ophthalmology) pipeline landscape.

Keratitis is an inflammation of the cornea. Symptoms include eye redness, eye pain, blurred vision, decreased vision and sensitivity to light. Risk factors include virus infections, injury, climatic condition and reduced immunity.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Keratitis Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Keratitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Keratitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Keratitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 7 and 1 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively for Keratitis.

Keratitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Keratitis (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Keratitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Keratitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Keratitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Keratitis (Ophthalmology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with p

  
Source:
Document ID
GMDHC8596IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Keratitis Overview71
Therapeutics Development82
  Pipeline Products for Keratitis Overview81
  Pipeline Products for Keratitis Comparative Analysis91
Keratitis Therapeutics under Development by Companies101
Keratitis Therapeutics under Investigation by Universities/Institutes111
Keratitis Pipeline Products Glance123
  Late Stage Products121
  Clinical Stage Products131
  Early Stage Products141
Keratitis Products under Development by Companies151
Keratitis Products under Investigation by Universities/Institutes161
Keratitis Companies Involved in Therapeutics Development177
  Adamis Pharmaceuticals Corporation171
  Dompe Farmaceutici S.p.A.181
  NanoViricides, Inc.191
  ReceptoPharm, Inc.201
  RegeneRx Biopharmaceuticals, Inc.211
  SIFI S.p.A221
  The Medicines Company231
Keratitis Therapeutics Assessment249
  Assessment by Monotherapy Products241
  Assessment by Target252
  Assessment by Mechanism of Action272
  Assessment by Route of Administration292
  Assessment by Molecule Type312
Drug Profiles3327
  acyclovir sodium Drug Profile331
  B-2088 Drug Profile341
  C-31G Drug Profile352
  dipyridamole Drug Profile371
  Herpecide Drug Profile382
  IBN-1 Drug Profile401
  JDE-004 Drug Profile411
  PIM-45 Drug Profile421
  polihexanide Drug Profile431
  Recombinant Protein to Agonize p75NTR and Trk for Ophthalmology Drug Profile442
  RGN-259 Drug Profile467
  RPI-MN Drug Profile532
  Small Molecule for Neurotrophic Keratitis Drug Profile551
  Small Molecules to Inhibit ATM for Herpes Keratitis Drug Profile561
  Synthetic Peptides for Bacterial Keratitis and Wounds Drug Profile571
  targocil Drug Profile581
  tigecycline Drug Profile591
Keratitis Dormant Projects601
Keratitis Discontinued Products611
Keratitis Product Development Milestones627
  Featured News &Press Releases621
    Jun 01, 2016: RegeneRx and Lee's Pharm Announce Acceleration of RGN-259 Development in China621
    May 27, 2016: SIFI announces the conclusion of Phase I clinical trial for the development of PHMB an orphan drug for the treatment of Acanthamoeba Keratitis, a rare ocular disease621
    Jan 12, 2016: NanoViricides CEO Dr. Eugene Seymour to Present at the Biotech Showcase in San Fransisco on Wednesday631
    Dec 02, 2015: rhNGF, the Dompe Biotech Molecule for the Treatment of Neurotrophic Keratitis, Receives Orphan Drug Designation from the European Medicines Agency631
    Oct 21, 2015: RegeneRx Updates on U.S. Ophthalmic Clinical Trials641
    Sep 30, 2015: RegeneRx Receives $500,000 Milestone Payment With Enrollment of First Patient in U.S. Phase 2b/3 Dry Eye Trial641
    Sep 21, 2015: RegeneRx Announces First Patient Enrolled in Phase 3 U.S. Neurotrophic Keratopathy Clinical Trial with RGN-259651
    Oct 20, 2014: RegeneRx Allowed to Proceed with Phase 3 Using RGN-259 Eye Drops for the Treatment of Neurotrophic Keratopathy651
    Sep 25, 2014: EuCornea: Dompe wins the Best Poster Award for its preliminary data concerning the use of rhNGF in the treatment of neurotrophic keratitis661
    Jul 23, 2014: Dompe announces the Food and Drug Administration has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis671
    Feb 14, 2013: Dompe Announces Enrollment Of First Patient In First International Clinical Trial Of rhNGF For Treatment Of Neurotrophic Keratitis681
Appendix692
  Methodology691
  Coverage691
  Secondary Research691
  Primary Research691
  Expert Panel Validation691
  Contact Us691
  Disclaimer701

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Keratitis - Pipeline Review, H2 2016" Oct 29, 2016. Alacra Store. Nov 15, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Keratitis-Pipeline-Review-H2-2016-2088-16712>
  
APA:
Global Markets Direct - Market Research. (2016). Keratitis - Pipeline Review, H2 2016 Oct 29, 2016. New York, NY: Alacra Store. Retrieved Nov 15, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Keratitis-Pipeline-Review-H2-2016-2088-16712>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.